heart failure

Bottle, A., Newson, R., Faitna, P., Hayhoe, B., & Cowie, M. R. (2022). Risk prediction of mortality for patients with heart failure in England: observational study in primary care. Esc Heart Fail. http://doi.org/10.1002/ehf2.14250
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437
Birkeland, K. I., Bodegard, J., Banerjee, A., Kim, D. J., Norhammar, A., Eriksson, J. W., et al. (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75-85. http://doi.org/10.1111/dom.14189
James, G., Kim, J., Mellström, C., Ford, K. L., Jenkins, N. C., Tsang, C., et al. (2022). Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study. Clin Kidney J, 15, 758-770. http://doi.org/10.1093/ckj/sfab225
Bottle, A., Newson, R., Faitna, P., Hayhoe, B., & Cowie, M. R. (2022). Changes in heart failure management and long-term mortality over 10 years: observational study. Open Heart, 9. http://doi.org/10.1136/openhrt-2021-001888